Nab-paclitaxel plus S-1 followed by S-1 maintenance therapy as a first-line strategy for advanced pancreatic adenocarcinoma.

4117Background: Growing evidence support maintenance therapy (MT) offer clinical benefit in pancreatic, colorectal and lung cancers. In our phase II trial, nab-paclitaxel plus S-1 (NPS) showed enco...